Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor

World Journal of Gastroenterology

Volumn 16, Issue 37, 2010, Pages 4716-4724

  Zhang, Yun ^a   Cao, Hui ^a   Wang, Ming ^a   Zhao, Wen Yi ^a   Shen, Zhi Yong ^a   Shen, Dan Ping ^a   Ni, Xing Zhi ^a   Wu, Zhi Yong ^a   Shen, Yan Ying ^a   Song, Yan Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastrointestinal stromal tumor; Loss of heterozygosity; P16; Prognosis; Tumor suppressor gene

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 9P; CHROMOSOME LOSS; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENETIC RISK; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 77957812843     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i37.4716     Document Type: Article

References (29)

1. Sabah M, Cummins R, Leader M, Kay E. Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors. Mod Pathol 2004; 17: 1364-1371
2. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602: 73-87
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003; 54: 3-24
4. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465
5. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996; 56: 3331-3337
6. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68
7. Yang J, Du X, Lazar AJ, Pollock R, Hunt K, Chen K, Hao X, Trent J, Zhang W. Genetic aberrations of gastrointestinal stromal tumors. Cancer 2008; 113: 1532-1543
8. Haller F, Löbke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S, von Heydebreck A, Gunawan B, Langer C, Ramadori G, Sültmann H, Poustka A, Korf U, Füzesi L. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol 2008; 215: 253-262
9. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, Terracciano L, Pross M, Insabato L, Di Vizio D, Iesalnieks I, Dirnhofer S, Hartmann A, Heinrich M, Miettinen M, Roessner A, Tornillo L. Loss of p16 protein defines highrisk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005; 11: 638-645
10. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, Tsuneyoshi M. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005; 36: 828-837
11. Hansen MF, Cavenee WK. Genetics of cancer predisposition. Cancer Res 1987; 47: 5518-5527
12. Manolaraki MM, Arvanitis DA, Sourvinos G, Sifakis S, Koumantakis E, Spandidos DA. Frequent loss of heterozygosity in chromosomal region 9pter-p13 in tumor biopsies and cytological material of uterine cervical cancer. Cancer Lett 2002; 176: 175-181
13. Pylkkänen L, Sarlomo-Rikala M, Wessman M, Hämäläinen E, Sainio M, Husgafvel-Pursiainen K, Carpén O. Chromosome 22q alterations and expression of the NF2 gene product, merlin, in gastrointestinal stromal tumors. Hum Pathol 2003; 34: 872-879
14. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T, Miyajima K, Iwamoto Y, Tsuneyoshi M. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 2003; 201: 487-495
15. Gessner C, Liebers U, Kuhn H, Stiehl P, Witt C, Schauer J, Wolff G. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 2002; 19: 134-140
16. Hilton DA, Penney M, Evans B, Sanders H, Love S. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am J Surg Pathol 2002; 26: 472-478
17. Mäkitie AA, MacMillan C, Ho J, Shi W, Lee A, O'Sullivan B, Payne D, Pintilie M, Cummings B, Waldron J, Warde P, Irish J, Brown D, Gilbert R, Gullane P, Liu FF, Kamel-Reid S. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003; 9: 2177-2184
18. Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgó J, Langer C, Ramadori G, Sültmann H, Füzesi L. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 2005; 11: 6589-6597
19. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay JY, Hogendoorn PC. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2009; 15: 4191-4198
20. Huang HY, Huang WW, Lin CN, Eng HL, Li SH, Li CF, Lu D, Yu SC, Hsiung CY. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 2006; 13: 1633-1644
21. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, Gronchi A, Pierotti MA, Pilotti S. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 2005; 104: 159-169
22. Schmieder M, Wolf S, Danner B, Stoehr S, Juchems MS, Wuerl P, Henne-Bruns D, Knippschild U, Hasel C, Kramer K. p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia 2008; 10: 1154-1162
23. Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Løberg EM, Isaksen V, Eide TJ, Nielsen TO. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol 2008; 21: 46-53
24. Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 2007; 211: 287-295
25. Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, Xu J, Isaacs WB, Chang BL. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer 2009; 124: 734-738
26. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK, Risk JM. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 2006; 94: 561-568
27. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008; 452: 553-563
28. Pfeifer GP, Besaratinia A. Mutational spectra of human cancer. Hum Genet 2009; 125: 493-506
29. Ricci R, Arena V, Castri F, Martini M, Maggiano N, Murazio M, Pacelli F, Potenza AE, Vecchio FM, Larocca LM. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004; 122: 35-43